Bexion Pharmaceuticals key facts
as of Oct 2026- Operator of a biotechnology company intended to develop biologics targeting sphingolipid metabolism.
- Bexion Pharmaceuticals is valued at approximately $82.1M as of Oct 2026 (last reported valuation).
- It has raised $56.0M.
- Notable investors include Keyhorse Capital, CancerFree KIDS, Michael J. Fox Foundation, National Cancer Institute, Seedfunders — 6 tracked in total.
- Status: Privately Held (backing).
Bexion Pharmaceuticals's last reported valuation, Dec 2017. Nothing priced has surfaced since.
- ·Watch Bexion Pharmaceuticals: the Monday email on marks, rounds and moves
Bexion Pharmaceuticals funding rounds
No funding rounds for Bexion Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Bexion Pharmaceuticals valuation
Bexion Pharmaceuticals's last reported valuation was $82.1 million in Dec 2017. No priced round, secondary trade or fund mark has surfaced since.
Bexion Pharmaceuticals investors
6 investors are on record for Bexion Pharmaceuticals, including Keyhorse Capital, CancerFree KIDS, Michael J. Fox Foundation and National Cancer Institute.
About Bexion Pharmaceuticals
Operator of a biotechnology company intended to develop biologics targeting sphingolipid metabolism. The company helps to treat solid tumors and chemotherapy-induced peripheral neuropathy, enabling health professionals to program cell death, reduce proliferation, and immune system.
- Sector
- Healthcare
- HQ
- Covington, KY, United States
- Founded
- 2006
- Employees
- 22
- Website
- bexionpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.